Serotonergic neurotransmission in early Parkinson's disease: A pilot study to assess implications for depression in this disorder

World Journal of Biological Psychiatry

Volumn 11, Issue 6, 2010, Pages 781-787

  Beucke, Jan C ^a   Uhl, Idun ^b   Plotkin, Michail ^c   Winter, Christine ^c,d   Assion, Hans Jörg ^b   Endrass, Tanja ^a   Amthauer, Holger ^e   Kupsch, Andreas ^c   Juckel, Georg ^b  

^a HUMBOLDT UNIVERSITY   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^e OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

123I FP CIT SPECT; Depression; LDAEP; Parkinson's disease; Serotonin

Indexed keywords

SEROTONIN; SEROTONIN TRANSPORTER;

AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION COEFFICIENT; DEPRESSION; DISEASE SEVERITY; FEMALE; HUMAN; MALE; NEUROTRANSMISSION; PARKINSON DISEASE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SYMPTOM;

AGED; DEPRESSIVE DISORDER; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; EVOKED POTENTIALS, AUDITORY; FEMALE; HUMANS; LEVODOPA; MALE; MEMBRANE TRANSPORT PROTEINS; MIDDLE AGED; PARKINSON DISEASE; PILOT PROJECTS; RECEPTORS, SEROTONIN; SEROTONIN; SYNAPTIC TRANSMISSION; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 77955615920     PISSN: 15622975     EISSN: 18141412     Source Type: Journal    
DOI: 10.3109/15622975.2010.491127     Document Type: Article

References (48)

1. Azmitia EC. 2007. Serotonin and brain: Evolution, neuroplastic-ity, and homeostasis. Int Rev Neurobiol 77:31-56.
2. Beck AT, Ward CH, Mendelson M, Mock J, Erbraugh J. 1961. An inventory for measuring depression. Arch Gen Psychiatry 4:561-571.
3. Borah A, Mohanakumar KP. 2007. Long-term l-dopa treatment causes indiscriminate increase in dopamin levels at the cost of serotonin synthesis in discrete brain regions of rats. Cell Mol Neurobiol 27(8):985-996.
4. 125 I]iodosulpride. Neuroscience 20:117-155.
5. Carrillo-de-la-Pena MT. 1992. ERP augmenting/reducing and sensation seeking: a critical review. Int J Psychophysiol 12: 211-220.
6. Carta M, Lindgren HS, Lundblad M, Stancampiano R, Fadda F, Cenci MA. 2006. Role of striatal L-DOPA in the production of dyskinesia in 6-hydroxydopamine lesioned rats. J Neuro-chem 96:1718-1727.
7. Carta M, Carlsson T, Kirik D, Bjorklund A. 2007. Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats. Brain 130:1819-1833.
8. Chang L. 1978. Method for attenuation correction in radionu-clide computed tomography. Trans Nucl Sci 25:638-643.
9. Chen TJ, Yu YW, Chen MC, Wang SY, Tsai SJ, Lee TW. 2005. Serotonin dysfunction and suicide attempts in major depres-sives: an auditory event-related potential study. Neuropsycho-biology 52:28-36.
10. 3 H]citalopram. Neuroscience 54:691-699.
11. Devos D, Lefebvre L, Bordet R. 2010. Dopaminergic and non-dopaminergic pharmacological hypotheses for gait disorders in Parkinson's disease. Fundam Clin Pharmacol. Epub ahead of print.
12. Doder M, Rabiner EA, Turjanski N, Lees AJ, Brooks DJ. 2003. Tremor in Parkinson's disease and serotonergic dysfunction: an 11C-WAY 100635 PET study. Neurology 60:601-605.
13. Fahn S, Elton R. 1987. Members of the UPDRS Development Committee. Unified Parkinsońs Disease Rating Scale. In: Fahn S, Marsden SD, Goldstein M, et al. editors. Recent developments in Parkinson ́ s disease II. New York: Macmillan, pp 111-123.
14. Fox SH, Chuang R, Brotchie JM. 2009. Serotonin and Parkinson's disease: On movement, mood, and madness. Mov Dis 24(9):1255-1266.
15. Gil S, Park C, Lee J, Koh H. 2010. The roles of striatal serotonin and l:-amino-acid decarboxylase on l-dopa-induced dyskinesia in a hemiparkinsonian rat model. Cell Mol Neurobiol. Epub ahead of print.
16. Halliday GM, Li YW, Blumbergs PC, Joh TH, Cotton RG, Howe PR, et al. 1990a. Neuropathology of immunohistochemically identified brainstem neurons in Parkinson's disease. Ann Neu-rol 27:373-385.
17. Halliday GM, Blumbergs PC, Cotton RG, Blessing WW, Geffen LB. 1990b. Loss of brainstem serotonin-and substance P-containing neurons in Parkinson's disease. Brain Res 510:104-107.
18. Hamilton M. 1960. A rating scale for depression. J Neurol Neu-rosurg Psychiatry 23:56-62.
19. Hegerl U, Juckel G. 1993. Intensity dependence of auditory evoked potentials as an indicator of central serotonergic neurotransmis-sion: a new hypothesis. Biol Psychiatry 33:173-187.
20. Hegerl U, Juckel G, Moller HJ. 1996. Event related brain potentials as indicators of neurochemical dysfunctions in psychiatric patients. Nervenarzt 67:360-368.
21. Hegerl U, Gallinat J, Juckel G. 2001. Event-related potentials. Do they reflect central serotonergic neurotransmission and do they predict clinical response to serotonin agonists? J Affect Disord 62:93-100.
22. Hughes AJ, Daniel SE, Kilford L, Lees AJ. 1992. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55:181-184.
23. Jacobs BL, Azmitia EC. 1992. Structure and function of the brain serotonin system. Physiol Rev 72:165-229.
24. Juckel G, Molnar M, Hegerl U, Csépe V. 1997. Karmos G. Auditory-evoked potentials as indicator of brain serotonergic activity-first evidence in behaving cats. Biol Psychiatry 41:1181-1195.
25. Juckel G, Hegerl U, Molnar M, Csépe V, Karmos G. 1999. Auditory evoked potentials reflect serotonergic neuronal activity-a study in behaving cats administered drugs acting on 5-HT1A autoreceptors in the dorsal raphe nucleus. Neuropsychopharmacology 21:710-716.
26. Juckel G, Gallinat J, Riedel M, Sokullu S, Schulz C, Möller HJ, et al. 2003. Serotonergic dysfunction in schizophrenia assessed by the loudness dependence measure of primary auditory cortex evoked activity. Schizophr Res 64:115-124.
27. Kääriäinen TM, García-Horsman JA, Piltonen M., Huotari M, Männistö P T. 2008. Serotonergic activation after 2-week intrastriatal infusion of l-dopa and slow recovery of circling in rats with unilateral nigral lesions. Basic Clin Pharmacol Toxicol 102(3):300-307.
28. Kulisevsky J, Pagonabarraga J, Pacual-Sedano B, Gironell A, García-Sánchez C, Martínez-Corral M. 2008. Motor changes during sertraline treatment in depressed patients with Parkinson's disease. Eur J Neurol 15:953-959.
29. Le MM, Simon H. 1991. Mesocorticolimbic dopaminergic network: functional and regulatory roles. Physiol Rev 71: 155-234.
30. Leentjens AF, Van Den Akker M, Metsemakers JF, Lousberg R, Verhey FR. 2003. Higher incidence of depression preceding the onset of Parkinson's disease: a register study. Mov Disord 18:414-418.
31. Linka T, Muller BW, Bender S, Sartory G. 2004. The intensity dependence of the auditory evoked N1 component as a predictor of response to Citalopram treatment in patients with major depression. Neurosci Lett 367:375-378.
32. Linka T, Muller BW, Bender S, Sartory G, Gastpar M. 2005. The intensity dependence of auditory evoked ERP components predicts responsiveness to reboxetine treatment in major depression. Pharmacopsychiatry 38:139-143.
33. Mayeux R. 1990. The ' serotonergic hypothesis ' for depression in Parkinson's disease. Adv Neurol 53:163-166.
34. Mendlin A, Martin FJ, Jacobs BL. 1999. Dopaminergic input is required for increases in serotonin output produced by behavioral activation: an in vivo microdialysis study in rat forebrain. Neuroscience 93:897-905.
35. Nagatsu T, Sawada M. 2009. L-dopa therapy for Parkinson's disease: Past, present, and future. Parkinsonism Relat Disord 15(Suppl 1):3-8.
36. Nilsson FM, Kessing LV, Sorensen TM, Andersen PK, Bolwig TG. 2002. Major depressive disorder in Parkinson's disease: a register-based study. Acta Psychiatr Scand 106:202-211.
37. Norra C, Mrazek M, Tuchtenhagen F, Gobbelé R, Buchner H, Sass H, et al. 2003. Enhanced intensity dependence as a marker of low serotonergic neurotransmission in borderline personality disorder. J Psychiatr Res 37:23-33.
38. O'Neill BV, Croft RJ, Leung S, Guille V, Galloway M, Phan KL, et al. 2006. Dopamine receptor stimulation does not modulate the loudness dependence of the auditory evoked potential in humans. Psychopharmacology (Berlin) 188:92-99.
39. Paige SR, Fitzpatrick DF, Kline JP, Balogh SE, Hendricks SE. 1994. Event-related potential amplitude/intensity slopes predict response to antidepressants. Neuropsychobiology 30: 197-201.
40. Peyron C, Luppi PH, Kitahama K, Fort P, Hermann DM, Jouvet M. 1995. Origin of the dopaminergic innervation of the rat dorsal raphe nucleus. Neuroreport 6:2527-2531.
41. Pogarell O, Tatsch K, Juckel G, Hamann C, Mulert C, Pöpperl G, et al. 2004. Serotonin and dopamine transporter availabilities correlate with the loudness dependence of auditory evoked potentials in patients with obsessive-compulsive disorder. Neuropsychopharmacology 29:1910-1917.
42. Pogarell O, Poepperl G, Mulert C, Hamann C, Sadowsky N, Riedel M, et al. 2005. SERT and DAT availabilities under citalopram treatment in obsessive-compulsive disorder (OCD). Eur Neuropsychopharmacology 15:521-524.
43. Schrag A, Barone P, Brown RG, Schrag A, Barone P, Brown RG, et al. 2007. Depression rating scales in Parkinson's disease: critique and recommendations. Mov Disord 22:1077-1092.
44. Sodhi MS, Sanders-Bush E. 2004. Serotonin and brain development. Int Rev Neurobiol 59:111-174.
45. Taylor TN, Caudle WM, Shepherd KR, Noorian A, Jackson CR, Iuvone PM, Weinshenker D, Greene JG, Miller GW. 2009. Nonmotor symptoms of Parkinson's disease revealed in an animal model with reduced monoamine storage capacity. J Neurosci 24:8103-8113.
46. Walter U, Hoeppner J, Prudente-Morrissey L, Horowski S, Herpertz SC, Benecke R. 2007. Parkinson's disease-like midbrain sonography abnormalities are frequent in depressive disorders. Brain 130:1799-1807.
47. Wang Y, Jeng CH, Lin JC, Wang JY. 1996. Serotonin modulates ethanol-induced depression in cerebellar Purkinje neurons. Alcohol Clin Exp Res 20:1229-1236.
48. Winter C, von Rumohr A, Mundt A, Petrus D, Klein J, Lee T, et al. 2007. Lesions of dopaminergic neurons in the substantia nigra pars compacta and in the ventral tegmental area enhance depressive-like behavior in rats. Behav Brain Res 184:133-141.